EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Real-world outcomes of stereotactic body radiotherapy plus sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus

Bin Zhou, Zihui Ma, Lei Wang, Yue Lu, Xi Cheng, Yabo Jiang, Xubiao Wei, Chongde Lu, Shuqun Cheng, Xingsheng Lu iD

The Oncologist · 2026

DOI: 10.1093/oncolo/oyaf439 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, 2026. Verfasst von Bin Zhou und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hepatopancreatobiliary Surgery, The Fourth Affiliated Hospital of Soochow University, Suzhou, 215000, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Bevacizumab, Liver Neoplasms, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Shanghai Municipal Health Commission Health Industry Clinical Research Special, Shanghai Municipal Science and Technology Commission, Naval Medical University and Eastern Hepatobiliary Surgery Hospital.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Sintilimab plus bevacizumab (Sin + Bev) is recommended as a first-line treatment for hepatocellular carcinoma (HCC) with portal vein tumor thrombus (PVTT); however, its efficacy remains limited. This study aimed to assess the efficacy and safety of stereotactic body radiotherapy (SBRT) combined with Sin + Bev for HCC with PVTT. Patients and Methods This retrospective study included 69 HCC patients with PVTT treated at two centers in China from August 2021 to December 2022. Patients received either SBRT + Sin + Bev (n = 31) or Sin + Bev alone (n = 38). Primary endpoints were overall survival (OS) and progression-free survival (PFS). Secondary endpoints included objective response rate (ORR) and treatment-related adverse events (TRAEs).

Results

Baseline characteristics showed similar distributions between the two groups. SBRT + Sin + Bev group showed a significant increase in both median OS (18.9 vs 9.3 months, P < .001), median PFS (9.1 vs 4.7 months, P = .0015), and ORR (64.6% vs 26.3%, P = .031) compared to Sin + Bev group. TRAEs in SBRT + Sin + Bev group were mostly manageable and acceptable compared to Sin + Bev group. Multivariate analysis confirmed that SBRT + Sin + Bev was an independent prognostic factor for better OS (P < .001) and better PFS (P < .001).

Conclusion

SBRT combined with sintilimab plus bevacizumab appears to improve treatment efficacy and demonstrates a favorable safety and feasibility profile for HCC with PVTT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularBevacizumabLiver NeoplasmsAntibodies, Monoclonal, HumanizedRadiosurgeryPortal VeinAntineoplastic Combined Chemotherapy ProtocolsVenous ThrombosisHumansMaleFemaleMiddle AgedRetrospective StudiesAgedAdultTreatment Outcome

Stichwörter der Autor:innen

bevacizumabhepatocellular carcinomaportal vein tumor thrombusreal-world studysintilimabstereotactic body radiotherapy

Substanzen

BevacizumabAntibodies, Monoclonal, Humanizedsintilimab

Autor:innen und Institutionen

  • Department of Hepatopancreatobiliary Surgery, The Fourth Affiliated Hospital of Soochow University, Suzhou, 215000, China.
  • Department of Hepatic Surgery VI, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, 200438, China.
  • Department of Radiotherapy, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, 200438, China.

ORCID-Profile: Xingsheng Lu

Förderung

  • Shanghai Municipal Health Commission Health Industry Clinical Research Special
  • Shanghai Municipal Science and Technology Commission
  • Naval Medical University and Eastern Hepatobiliary Surgery Hospital
  • Clinical Key Disease Diagnosis and Treatment Technology Project of Suzhou Municipal Health Commission

Zitieren

APA

Zhou, B., Ma, Z., Wang, L., Lu, Y., Cheng, X., Jiang, Y., Wei, X., Lu, C., Cheng, S., & Lu, X. (2026). Real-world outcomes of stereotactic body radiotherapy plus sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus. The Oncologist. https://doi.org/10.1093/oncolo/oyaf439

Vancouver

Zhou B, Ma Z, Wang L, Lu Y, Cheng X, Jiang Y, et al. Real-world outcomes of stereotactic body radiotherapy plus sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus. The Oncologist. 2026. doi:10.1093/oncolo/oyaf439

BibTeX
@article{Zhou2026,
  author = {Zhou, Bin and Ma, Zihui and Wang, Lei and Lu, Yue and Cheng, Xi and Jiang, Yabo and Wei, Xubiao and Lu, Chongde and Cheng, Shuqun and Lu, Xingsheng},
  title = {Real-world outcomes of stereotactic body radiotherapy plus sintilimab and bevacizumab for hepatocellular carcinoma with portal vein tumor thrombus},
  journal = {The Oncologist},
  year = {2026},
  doi = {10.1093/oncolo/oyaf439}
}
Kostenlos starten →